Cargando…

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

PURPOSE: To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus the current mix of reimbursed biologics for treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soini, Erkki, Asseburg, Christian, Taiha, Maarit, Puolakka, Kari, Purcaru, Oana, Luosujärvi, Riitta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656723/ https://www.ncbi.nlm.nih.gov/pubmed/28975568 http://dx.doi.org/10.1007/s12325-017-0614-8

Ejemplares similares

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol
por: Hazes, Johanna M., et al.
Publicado: (2010)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2015)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
por: Smolen, J S, et al.
Publicado: (2015)

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Hannech, Emna, et al.
Publicado: (2021)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis
por: Rosa, J, et al.
Publicado: (2010)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis
por: Sakai, Hiroyuki, et al.
Publicado: (2017)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland
por: Puolakka, K, et al.
Publicado: (2012)

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
por: Mease, Philip J.
Publicado: (2011)

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
por: Bykerk, V P, et al.
Publicado: (2015)

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
por: Carron, Philippe, et al.
Publicado: (2016)

Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis
por: Nozaki, Yuji, et al.
Publicado: (2021)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity
por: Pope, Janet, et al.
Publicado: (2015)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
por: Mendonça, José Alexandre, et al.
Publicado: (2019)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
por: Paul, Stéphane, et al.
Publicado: (2020)

Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Koda, Keigo, et al.
Publicado: (2020)

Eosinophilic Annular Erythema due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
por: Bassi, Andrea, et al.
Publicado: (2023)

Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland
por: Puolitaival, Antti, et al.
Publicado: (2022)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
por: Almuhanna, Nouf, et al.
Publicado: (2023)

Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland
por: Kumar, Namita, et al.
Publicado: (2018)

Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_mdvr7duvo0hnnq7em3qfuaa9oi